Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
California’s Medicaid program spent the most of all states on GLP-1 coverage, exceeding $1.4 billion, or $118 per enrollee.
Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO 0.15%) stock crashed ...
Unless the government intervenes to lower the price or forces insurers to cover the drugs, they will remain out of range for ...
After years of rising obesity rates in the US, the numbers dipped slightly during 2023, though experts disagree about the ...
Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...
An international committee of experts will release an interim report in early 2025 outlining criteria for diagnosing ...